Abbhi Capital

Clinical Research IO is a health technology company based in Boston, Massachusetts, that specializes in developing e-source and site operation software for clinical research sites. The company's software allows users to create and customize clinical trial documentation using a library of pre-developed templates, while also detecting and correcting source data errors. Additionally, it includes features for managing patient compliance, such as scheduling and text reminders, as well as modules for patient scheduling and recruitment, aimed at enhancing participant retention and recruitment efforts. By providing a unified system for data capture, Clinical Research IO facilitates the regulatory workflows of pharmaceutical companies, biotechnology firms, research sites, and academic research centers, thereby streamlining the overall clinical research process.

BrainStorm Cell Therapeutics Inc. is a biotechnology company focused on developing and commercializing adult stem cell therapies for neurodegenerative diseases. Their proprietary technology, NurOwn, utilizes a patient's own mesenchymal stem cells, which are engineered to produce neurotrophic factors that promote neuronal survival. The company is actively advancing NurOwn through clinical trials for conditions such as amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Parkinson's disease. Currently, NurOwn is in a Phase III clinical trial for ALS and a Phase II trial for MS, with plans for preclinical studies targeting Parkinson’s disease, Huntington’s disease, and autism spectrum disorder. BrainStorm has partnered with Catalent for the manufacturing of NurOwn, ensuring the production of this autologous cellular therapy. Founded in 2000 and headquartered in New York, BrainStorm Cell Therapeutics was previously known as Golden Hand Resources Inc. before rebranding in 2004.